VAFP
ITCI

Vahanian & Associates Financial Planning’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Vahanian & Associates Financial Planning’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$710K Sell
9,917
-5,300
-35% -$305K 2.81% 9
2023
Q3 		$793K Hold
15,217
– – 2.55% 9
2023
Q2 		$964K Sell
15,217
-915
-6% -$57K 3.05% 8
2023
Q1 		$874K Sell
16,132
-2,460
-13% -$119K 2.42% 9
2022
Q4 		$984K Sell
18,592
-8,200
-31% -$411K 3.22% 7
2022
Q3 		$1.25M Sell
26,792
-10,900
-29% -$569K 4.29% 4
2022
Q2 		$2.15M Sell
37,692
-7,841
-17% -$445K 9.25% 2
2022
Q1 		$2.79M Sell
45,533
-26,209
-37% -$1.36M 6.44% 3
2021
Q4 		$3.75M Buy
+71,742
New +$3.01M 3.03% 6

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vahanian & Associates Financial Planning's ITCI Position: Q4 2023 in Review

Vahanian & Associates Financial Planning reduced its Intra-Cellular Therapies Inc. (ITCI) stake by 35% in Q4 2023, selling an estimated $305K and leaving 9,917 shares worth $710K. The position accounts for 2.81% of the portfolio, ranked #9.

Vahanian & Associates Financial Planning first reported a position in ITCI in Q4 2021 and has held it in 9 quarters since. The position peaked at $3.75M in Q4 2021. 333 funds tracked by Wall St. Rank hold ITCI as of Q4 2023.

  • Vahanian & Associates Financial Planning held 9,917 shares of Intra-Cellular Therapies Inc. worth $710K as of Q4 2023.
  • Vahanian & Associates Financial Planning sold 5,300 Intra-Cellular Therapies Inc. shares in Q4 2023, an estimated $305K.
  • Intra-Cellular Therapies Inc. made up 2.81% of Vahanian & Associates Financial Planning's portfolio in Q4 2023, its #9 holding.
  • Vahanian & Associates Financial Planning first reported a position in Intra-Cellular Therapies Inc. in Q4 2021 and has held it in 9 quarters since.
  • Vahanian & Associates Financial Planning's Intra-Cellular Therapies Inc. position peaked at $3.75M in Q4 2021.
  • 333 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2023.

Based on Vahanian & Associates Financial Planning's 13F filing for Q4 2023, filed 25 Jan 2024.